Contract Research & Services
Clinical Trials
Search Results: Clinical Trials
1-15 of 5152 results
ImmuPharma completes phase 3 trial of Lupus drug
ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Allergy Therapeutics completes patient recruitment in PQ Birch phase III clinical trial
Allergy Therapeutics has completed recruitment of patients in the PQ Birch phase III clinical trial.
Contract Research & Services > Clinical Trials > News
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 in NSCLC
BerGenBio announced that it met the first efficacy endpoint in the phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved EGFR inhibitor.
Contract Research & Services > Clinical Trials > News
Inovio, Parker Institute to jointly evaluate cancer immunotherapy combinations
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy have signed a clinical collaboration agreement to assess novel combination regimens within the field of immuno-oncology.
Contract Research & Services > Clinical Trials > News
Axovant scraps dementia drug development after negative results
By PBR Staff Writer
Axovant Sciences said it will no longer develop intepirdine, its lead candidate for dementia, after failing to meet several goals in recent studies.
Contract Research & Services > Clinical Trials > News
Momenta, Mylan to start trial of biosimilar to eye drug Eylea
By PBR Staff Writer
Momenta Pharmaceuticals and Mylan have unveiled plans to commence pivotal clinical study of a biosimilar to Regeneron’s eye drug Eylea (aflibercept).
Contract Research & Services > Clinical Trials > News
Centrexion secures funding to begin trial of knee osteoarthritis pain drug
By PBR Staff Writer
Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).
Contract Research & Services > Clinical Trials > News
Atara gets FDA approval to start two phase 3 studies to assess tabelecleucel in patients with EBV+PTLD
Atara Biotherapeutics has received clearance from the US Food and Drug Administration (FDA) to initiate two phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).
Contract Research & Services > Clinical Trials > News
Study shows experimental diabetes drug could enhance Alzheimer’s signs in mice
By PBR Staff Writer
A study conducted by the UK and Chinese researchers showed that an experimental diabetes drug may have improved the memory and brain function in mice with symptoms of Alzheimer’s disease.
Contract Research & Services > Clinical Trials > News
AbbVie's upadacitinib succeeds in phase 3 rheumatoid arthritis study
AbbVie says that its investigational oral JAK1-selective inhibitor upadacitinib (ABT-494) has demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.
Contract Research & Services > Clinical Trials > News
Bristol-Myers makes equity investment in Taris Biomedical
By PBR Staff Writer
Bristol-Myers Squibb has made an equity investment in Taris Biomedical, a therapeutically urology company engaged in the development of treatments for patients suffering from difficult-to-treat bladder diseases.
Contract Research & Services > Clinical Trials > News
Pfizer, Array BioPharma to study different anti-cancer combinations
By PBR Staff Writer
Array BioPharma has established a clinical trial collaboration with Pfizer to study the safety and efficacy of various anti-cancer combinations.
Contract Research & Services > Clinical Trials > News
Regeneron and ISA Pharmaceuticals form immuno-oncology collaboration
Regeneron Pharmaceuticals and ISA Pharmaceuticals have formed a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody.
Contract Research & Services > Clinical Trials > News
Allergan, Richter’s bipolar depression drug meets primary end point in phase 3 study
By PBR Staff Writer
Allergan and Gedeon Richter have announced that cariprazine met primary end point in a phase 3 study to treat bipolar I depression.
Contract Research & Services > Clinical Trials > News

PBR Supplier Recommendations

CTL Laboratories - Contract Immune Monitoring and Research
Cellular Technology Limited (CTL), headquartered in Shaker Heights, OH, is a privately held biotechnology company that built its reputation as the global leader in the ELISPOT field over the past two decades by establishing the ELISPOT instrumentation and scientific principles that have helped to define the parameters of ELISPOT research for monitoring of Cell-Mediated Immunity.... Contract Research & Services > Clinical Trials > Suppliers
See more

PBR White Paper Recommendations

Cellular Technology Limited: A multicolor Natural Killer cell-mediated cytotoxicity detection By CTL Laboratories
A multicolor Natural Killer cell-mediated cytotoxicity detection using fluorescence and direct cell imaging.... Contract Research & Services > Clinical Trials > White Papers User vs. Software-Dependent Variability of ELISPOT Counts Obtained from ten Different Laboratories By CTL Laboratories
In ELISPOT assays, cytokine spots produced by antigen-specific T cells show a broad spectrum of sizes and densities over variable background. Therefore, even experienced investigators are likely to come up with different spot counts when subjectively judging the minimal spot size/density to be counted and the maximal spot size for the cut off between singlecell-derived spots vs. those created by cell clusters. This study aims to find out whether statistics-based automated gating can harmonize spot counts obtained in different laboratories.... Contract Research & Services > Clinical Trials > White Papers ELISPOT Assays Provide Reproducible Results Among Different Laboratories for T-cell Immune Monitoring - Even in Hands of ELISPOT's Inexperienced Investigators By CTL Laboratories
Measurements of antibodies in bodily fluids (e.g., by ELISA) have provided robust and reproducible results for decades and such assays have been validated for monitoring of B-cell immunity. In contrast, measuring T-cell immunity has proven to be a challenge due to the need to test live cells in functional assays ex vivo. Several previous efforts looking into the reproducibility of ex vivo T-cell assays between different laboratories, or even within the same laboratory, have provided rather discouraging results.... Contract Research & Services > Clinical Trials > White Papers How Frequently are Predicted Peptides Actually Recognised by CD8 Cells? By CTL Laboratories
Detection of antigen-specific CD8 cells relies on the use of peptides that can bind to HLA-Class I molecules. There is extensive knowledge on individual HLA-alleles’ peptide binding requirements and for many antigens immunogenic peptides have been defined. The 32 individual peptides that comprise the CEF peptide pool represent such well-defined peptide determinants for Cytomegalo, Epstein Barr, and Flu virus. We tested 42 healthy human donors on the accuracy of these peptide predictions.... Contract Research & Services > Clinical Trials > White Papers Four-Colour B Cell ELISPOT Assay for Simultaneous Detection of all Four Human IgG Subclasses By CTL Laboratories
ELISPOT assays are a key research tool for enumerating antigen-specific B cells.... Contract Research & Services > Clinical Trials > White Papers See more
1-15 of 5152 results